Independent Research
TXG Analysis
3 pieces of research on 10x Genomics, Inc.. We find the signal management buried in the earnings call.
3signal analyses
0news briefs
latest: Aug 23, 2026
Signal Analysis (3)
Analysis
10x Genomics Trades Past Analyst Target, Atera Test Looms
An analyst upgraded 10x Genomics this week and declared the Atera turnaround "real," yet shares already trade at $65.12, above the $49.54 consensus price target…
Read analysis →Analysis
10x Genomics Clears Analyst Target, Insiders Keep Selling
10x Genomics shares have rallied to $65.12, surpassing the analyst consensus price target of $49.54, after August earnings prompted upgrades citing Atera produc…
Read analysis →Analysis
10x Genomics: Four Beats, Falling Revenue, Insiders Sell
10x Genomics delivered a fourth consecutive EPS beat, posting $0.0264 against a consensus of -$0.017, even as trailing revenue fell 12.7% to $620 million. The s…
Read analysis →